{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"59.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic analysis set (PKAS) included all randomized participants (SAF) who received cemiplimab and who had at least 1 non-missing cemiplimab concentration following the first dose of cemiplimab up to the end of the study.","reportingStatus":"POSTED","timeFrame":"Up to 73.5 months","title":"Trough Concentration (Ctrough) of Cemiplimab in Serum","type":"SECONDARY","unitOfMeasure":"milligrams per liter (mg/L)"}